ISMP received a report recently about confusion between Activase (alteplase 50 mg and 100 mg) and Cathflo Activase (alteplase 2 mg). We previously published recommendations (in 2008) to: communicate the purpose of the drug, communicate complete orders (i.e., dose, route, administration directions), use disease-specific ordersets in non-emergent situations, and avoid the abbreviation “tPA”.
Just curious, but what additional strategies is your institution using to avoid medication errors with these two products?
Thanks!
Mike